Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherWages, Salaries and Other
Ratios

Spero Therapeutics (SPRO) EBIAT (2016 - 2025)

Spero Therapeutics' EBIAT history spans 10 years, with the latest figure at $31.5 million for Q4 2025.

  • For Q4 2025, EBIAT rose 250.81% year-over-year to $31.5 million; the TTM value through Dec 2025 reached $8.5 million, up 112.41%, while the annual FY2025 figure was $8.6 million, 112.5% up from the prior year.
  • EBIAT reached $31.5 million in Q4 2025 per SPRO's latest filing, up from -$7.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $51.2 million in Q4 2023 to a low of -$32.8 million in Q1 2022.
  • Average EBIAT over 5 years is -$8.7 million, with a median of -$13.6 million recorded in 2023.
  • Peak YoY movement for EBIAT: crashed 435.84% in 2024, then soared 250.81% in 2025.
  • A 5-year view of EBIAT shows it stood at -$29.3 million in 2021, then soared by 191.42% to $26.8 million in 2022, then soared by 91.22% to $51.2 million in 2023, then tumbled by 140.83% to -$20.9 million in 2024, then skyrocketed by 250.81% to $31.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's EBIAT are $31.5 million (Q4 2025), -$7.4 million (Q3 2025), and -$1.7 million (Q2 2025).